Log in to your Inderes Free account to see all free content on this page.

Carasent

23.905

SEK

+4.62 %

1,662 following

CARA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview

Ownership

Investor consensus

+4.62%

+15.48%

+9.41%

+7.68%

+24.31%

+65.18%

+3.02%

+59.25%

+8.08%

Carasent is an IT company. The company delivers a wide range of products and services in communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security solutions. Customers are mainly found in health and care, finance, and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.

Market cap

1.73B SEK

Turnover

5.75M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

10.7.

2025

Interim report Q2'25

16.10.

2025

Interim report Q3'25

12.2.

2026

Annual report '25

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release4/23/2025, 1:12 PM

Annual General Meeting in Carasent AB (publ)

Press release4/14/2025, 2:08 PM

Redeye: Carasent - AI initiatives in focus

Press release4/14/2025, 5:10 AM

Carnegie Access: Carasent: Solid start to the year – Q1 review

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release4/11/2025, 8:01 AM

Carnegie Access: Carasent: Strong growth in Q1 – initial comment

Carasent, Audiocast with teleconference, Q1'25

Webcast4/11/2025, 6:00 AM

Carasent, Audiocast with teleconference, Q1'25

Regulatory press release4/11/2025, 5:00 AM

Carasent AB (publ) – interim report Q1 2025

Regulatory press release4/7/2025, 1:30 PM

Carasent AB (publ) – Invitation to presentation of Q1 2025 results

Press release4/2/2025, 3:54 PM

Carnegie Access: Carasent: The scene is set for 2025 – Q1 preview

Press release3/31/2025, 8:01 AM

Carnegie Access: Analyspodden 326: Carasent & Carnegies analytiker Elvin Rolder

Regulatory press release3/24/2025, 4:00 PM

Carasent publishes Annual Report for 2024

Regulatory press release3/24/2025, 7:00 AM

Notice of Annual General Meeting in Carasent AB (publ)

Press release3/21/2025, 12:05 PM

The Administrative Court rejects the healthcare providers' appeal to remove the requirement for Millennium in primary care in VGR

Press release3/12/2025, 5:17 AM

Carnegie Access: Carasent: Impressions from Carnegie’s Healthcare Conference

Regulatory press release2/21/2025, 12:08 PM

Proposal for election of the board of Carasent AB (publ)

Press release2/17/2025, 7:21 AM

Redeye: Carasent - Back in Shape in 2024 – More to Come

Press release2/14/2025, 7:00 AM

Carnegie Access: Carasent: Well-positioned for 2025 – Q4 review

Press release2/13/2025, 7:57 AM

Carnegie Access: Carasent: Solid end to the year – Q4 initial

Carasent, Audiocast with teleconference, Q4'24

Webcast2/13/2025, 7:00 AM

Carasent, Audiocast with teleconference, Q4'24

Regulatory press release2/13/2025, 6:00 AM

Carasent AB (publ) – Year-end report January–December 2024

Regulatory press release2/10/2025, 5:00 PM

Carasent AB (publ) – Invitation to presentation of Q4 2024 results

Forum discussions

Carnegielta commissioned research pre-Q4 Inderes Carnegie Access: Carasent: We expect a solid end to the year – Q4 preview -... Carnegie has published a new commissioned research report on Carasent.To access the full report and subscribe to future updates, visit https://www.carnegie...

1/29/2025, 6:41 AM

by timontti

6

redeye.se Carasent: Back in Shape in 2024 – More to Come Redeye retains its positive view of Carasent following the Q4 report. Despite a somewhat softer Q4 report than expected and a softened outlook for H1 2025, we changed our Base Case driven by revised New Base Case SEK28 (NOK26...

2/17/2025, 6:47 AM

by timontti

1

Redeye odotuksia 13.2. osariin

2/6/2025, 3:08 PM

by timontti

1

Inderes First day of trading in Carasent AB (publ) on Nasdaq Stockholm - Inderes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND...

12/9/2024, 9:27 AM

by timontti

1

Sisäpiiriostot jatkuvat tällä kertaa huikealla ~5k€ panostuksella

11/22/2024, 1:53 PM

by timontti

1

Carnegielta 64-sivuinen analyysiraportti. Saa ilmaiseksi ao. linkistä joten jaan pdf:n tänne suoraan https://www.carnegie.se/en/commissioned-research/carasent/ carasent151124.pdf (3,9 Mt)

11/15/2024, 6:39 AM

by timontti

1

https://www.carnegie.se/en/commissioned-research/carasent/ ja redeye.se Carasent Q4: Slightly Softer than Expected Redeye comments on Carasent’s Q4 report, showing slightly softer numbers than expected. However, our positive long-term view is unchanged.

2/13/2025, 8:52 AM

by timontti

0

Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.